• Yuexin joined Andera Life Sciences team as investment director in 2021.
  • Before joining Andera, Yuexin was vice president at 3H Health Investment Management Hong Kong and Shanghai, where he made leading contributions to biotech portfolio including InnoCare (9969.HK), KeyMed (1877.HK) and EdiGene. Prior to that, he gained various experiences in pharma and biotech sectors as project manager at Merck, business development associate at Biotheranostics (acquired by Hologic) and analyst at Mérieux Développement.
  • Yuexin holds BPharm from Shanghai Jiao Tong University and Master in Management from HEC.
  • Yuexin speaks Chinese, English and French.